GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (ASX:BLT) » Definitions » Tax Rate %

Benitec Biopharma (ASX:BLT) Tax Rate % : 0.00% (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Benitec Biopharma Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Benitec Biopharma's Tax Expense for the three months ended in Mar. 2024 was A$0.00 Mil. Benitec Biopharma's Pre-Tax Income for the three months ended in Mar. 2024 was A$-6.53 Mil. Therefore, Benitec Biopharma's Tax Rate % for the quarter that ended in Mar. 2024 was 0.00%.


Benitec Biopharma Tax Rate % Historical Data

The historical data trend for Benitec Biopharma's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Tax Rate % Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Benitec Biopharma Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Benitec Biopharma's Tax Rate % for the fiscal year that ended in Jun. 2023 is calculated as

Tax Rate %=Tax Expense (A: Jun. 2023 )/Pre-Tax Income (A: Jun. 2023 )
=0/-29.147
=0.00 %

Benitec Biopharma's Tax Rate % for the quarter that ended in Mar. 2024 is calculated as

Tax Rate %=Tax Expense (Q: Mar. 2024 )/Pre-Tax Income (Q: Mar. 2024 )
=0/-6.525
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Benitec Biopharma Tax Rate % Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (ASX:BLT) Business Description

Traded in Other Exchanges
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Benitec Biopharma (ASX:BLT) Headlines

From GuruFocus

John Rogers Increases Stake in Blount International

By Tiziano Frateschi Tiziano Frateschi 04-13-2015

Jean-Marie Eveillard Sells More Blount International

By Holly LaFon Holly LaFon 10-09-2012

Blount International Inc. (BLT) CEO International Inc Blount buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-01-2009

Ariel Fund Quarterly Commentary From John Rogers

By Holly LaFon Holly LaFon 01-21-2016

Blount International Inc. (BLT) CEO Joshua L Collins buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-13-2009